Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Oleg E. Akilov et al.|The Lancet|2017Cited by 580
The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patientsJulia Scarisbrick, Andrew Bates, Pietro Quaglino et al.|British Journal of Dermatology|2018Cited by 235
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023Johanna Latzka, Franz Trautinger, Chalid Assaf et al.|European Journal of Cancer|2023Cited by 164
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International ConsortiumPietro Quaglino, C. Ram‐Wolff, Milena Maule et al.|Annals of Oncology|2017Cited by 136
Subcellular immune interactions reveal a MHC class I related mechanism of immune evasion in cutaneous T-cell lymphomaPacôme Prompsy, Emmanuella Guenova, Christoph Iselin et al.|European Journal of Cancer|2025Cited by 0